|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Crohn’s disease-Defect in innate defence显示文摘Crohn’s disease may prinicipally involve the whole gastrointestinal tract. Most commonly, the inflammation occurs in the small intestine and/or in the colon with stable disease location over the years. The pathogenesis of both disease phenotypes is complex, the likely primary defect lies in the innate rather than adaptive immunity, particularly in the chemical antimicrobial barrier of the mucosa. Crohn’s ileitis is associated with a reduced expression of the Wnt signalling pathway transcription factor T-cell factor 4 (TCF4), which is regulating Paneth cell differentiation. As a result, the alpha-defensins and principal Paneth cell products HD5 and HD6 are deficiently expressed in ileal disease, independent of current inflammation. In contrast, Crohn’s colitis is typically associated with an impaired induction of the beta-defensins HBD2 and HBD3 caused by fewer gene copy numbers in the gene locus of the beta-defensins on chromosome 8. This ileal and colonic defect in innate defence mediated by a deficiency of the protective alpha- and beta- defensins may enable the luminal microbes to invade the mucosa and trigger the inflammation. A better understanding of the exact molecular mechanisms behind ileal and colonic Crohn’s disease may give rise to new therapeutic strategies based on a stimulation of the protective innate immune system. | Michael Gersemann Jan Wehkamp Klaus Fellermann Eduard Friedrich Stange | 2008 | World Journal of Gastroenterology2008，14，36： | 7 |
| 2 | Thiopurines in inflammatory bowel disease revisited显示文摘Although a great variety of new drugs have been introduced for the therapy of inflammatory bowel diseases so far,a definite cure of the disease is still out of scope.An anti-inflammatory approach to induce remission followed by maintenance therapy with immunosupressants is still the mainstay of therapy.Thiopurines comprising azathioprine and its active metabolite mercaptopurine as well as tioguanine,are widely used in the therapy of chronic active inflammatory bowel disease(IBD).Their steroid sparing potential and efficacy in remission maintenance are out of doubt.Unfortunately,untoward adverse events are frequently observed and may preclude further administration or be life threatening.This review will focus on new aspects of thiopurine therapy in IBD,its efficacy and safety. | Florian Br Christian Sina Klaus Fellermann | 2013 | World Journal of Gastroenterology2013，19，11： | 3 |
| 3 | Herpes simplex virus colitis complicating ulcerative colitis: A case report and brief review on superinfections显示文摘 | Marco Oliver Schunter Thorsten Walles Peter Fritz Uta Meyding-Lamadé Klaus-Peter Thon Klaus Fellermann Eduard Friedrich Stange Wolfram Lamadé | 2007 | Journal of Crohn’s and Colitis2007，，： | 2 |
| 4 | Mechanisms of disease:defensins in gastrointestinal disease显示文摘 | WEHKAMP J FELLERMANN K HERRLINGER KR | 2005 | Nat Clin Pract Gastroenterol Hepatol2005，2，： | 1 |
| 5 | Mechanisms of disease: defensins in gastrointestinal diseases 显示文摘 | Wehkamp J Fellermann K Herrlinger KR | 2005 | Nat Clin Pract Gastroenterol Hepatol2005，2，9： | 1 |
| 6 | Mechanisms of disease:defensins in gastrointestinal diseases 显示文摘 | Wehkamp J Fellermann K Herrlinger KR | 2005 | Nat Clin Pract Gastroenterol Hepatol2005，2，9： | 1 |
| 7 | Chronic inflammatory bowel diseases (IBD) :novel pathophysiological concepts and their clinical relevance 显示文摘 | Stange EF Schmid M Fellermann K | 2005 | Praxis2005，94，37： | 1 |
| 8 | Antimicrobial peptides in the skin 显示文摘 | Fellermann K Wehkamp J Stange EF | 2003 | N Engl J Med2003，348，4： | 1 |
| 9 | Crohn's disease:a defensin deficiency syndrome显示文摘 | Fellermann K Wehkamp J Herrlinger KR | | 0，，06： | 1 |
| 10 | Crohn's disease:a defensin deficiency syndrome显示文摘 | Klaus Fellermann Jan Wehkamp | 2003 | European J Gastroenterology & Hepatology2003，15，： | 1 |
| 11 | Differences in goblet cell differentiation between Crohn’s disease and ulcerative colitis显示文摘 | Michael Gersemann Svetlana Becker Irmgard Kübler Maureen Koslowski Guoxing Wang Klaus Robert Herrlinger Joscha Griger Peter Fritz Klaus Fellermann Matthias Schwab Jan Wehkamp Eduard Friedrich Stange | 2008 | Differentiation2008，，1： | 1 |
| 12 | Antimicrobial peptides in the skin显示文摘 | Fellermann K Wehkamp J Stange EF | 2003 | N Engl J Med2003，348，4： | 1 |
| 13 | Response of refractory colitis to intravenous or oral tacrilimus (FK506)显示文摘 | Fellermann K Tanko Z Herrlinger KR | 2002 | Imflamm Bowel Dis2002，8，5： | 1 |
| 14 | A flow cytometric assay to monitor antimicrobial activity of defensins and cationic tissue extracts显示文摘 | Nuding S Fellermann K Wehkamp J | 2006 | J Microbiol Meth2006，65，2： | 1 |
| 15 | Mechanisms of disease:defensins in gastrointestinal diseases 显示文摘 | WEHKAMP J FELLERMANN K HERRLINGER K R | 2005 | Nat Clin Pratt Gastroenteml Hepatol2005，2，9： | 1 |
| 16 | Defensin-innate immunity at the epithelial frontier显示文摘 | Fellermann K Stange EF | 2001 | Eur J Gastroenterol Hepatol2001，13，7： | 1 |
| 17 | Attenuated induction of epithelial and leukocyte serine antiproteases elafin and secretory leukocyte protease inhibitor in Crohn's disease显示文摘 | SCHMID M FELLERMANN K FRITZ P | 2007 | J Leukoc Biol2007，81，4： | 1 |
| 18 | Sweet syndrome and erythema nodosum in ulcerative colitis, refractory to steroids: successful treatment with tacrolimus 显示文摘 | FELLERMANN K RUDOLPH B WITTHOFT T | 2001 | Med Klin(Munich)2001，96，： | 1 |
| 19 | A chromosome 8 gene-cluster polymorphism with low human beta-defensln 2 gene copy number predisposes to Crohn disease of the colon显示文摘 | Fellermann K Stange DE Schaeffeler E | 2006 | Am J Hum Genet2006，79，3： | 1 |
| 20 | Innate Immunity and Colonic Inflammation: Enhanced Expression of Epithelial α-Defensins显示文摘 | J. Wehkamp B. Schwind K.R. Herrlinger S. Baxmann K. Schmidt M. Duchrow C. Wohlschl?ger A.C. Feller E.F. Stange K. Fellermann | 2002 | Digestive Diseases and Sciences2002，，6： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员